# A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

> **NCT02509039** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 15 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** CC-122

## Key facts

- **NCT ID:** NCT02509039
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-02
- **Primary completion:** 2023-05-09
- **Final completion:** 2023-05-09
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Replaced it with another clinical trial.
- **Last updated:** 2024-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02509039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02509039, "A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT02509039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*